Mycobacterium leprae Bacterial Load Test in Dubai | 800 AED | DHA Licensed

Item: Mycobacterium leprae Bacterial Load Test
Author: Dr. PRABHAKAR REDDY

Executive Summary & Core Metrics

Executive Summary: The Mycobacterium leprae Bacterial Load Test utilises quantitative Real-Time PCR and Whole Genome Sequencing to deliver 99.9% diagnostic sensitivity for leprosy bacilli detection and drug-resistance profiling. The service includes hospital-based sample collection under sterile conditions, temperature-controlled cold-chain transport, telephonic post-test clinical guidance, and direct insurance billing verification.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing.
Clinical Logistics: Hospital extraction only – all specimen collection is conducted strictly inside an accredited medical facility; mobile home phlebotomy is disabled for safety.
Clinical Guidance: Telephonic post-test result interpretation by qualified clinical coordinators.
Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The Mycobacterium leprae Bacterial Load Test employs quantitative Real-Time PCR to measure the exact number of leprosy bacilli per millilitre of specimen, complemented by Whole Genome Sequencing for strain confirmation and detection of mutations conferring resistance to dapsone, rifampicin, and ofloxacin. This dual-molecular approach empowers dermatologists and infectious disease specialists in the UAE to tailor multi-drug therapy, monitor bacillary clearance, and prevent relapse with precision.

Feature	Our Test (qPCR + WGS)	Closest Alternative (Slit-Skin Smear)
Diagnostic Sensitivity	99.9% (detects 1–10 bacilli/mL)	~50–70% (operator-dependent)
Methodology	Real-Time PCR (quantitative) + Whole Genome Sequencing	Microscopy (ZN stain), no molecular typing
Turnaround Time	Email report within 36 hours; phone notification within 24 hours	3–7 working days (culture often unavailable)
Drug Resistance Insight	Yes, via WGS (dapsone, rifampicin, ofloxacin gene targets)	None

Physician Insight & Safety Protocols

“As a consultant medical geneticist, I emphasise that the M. leprae bacterial load test provides quantitative genomic data critical for monitoring therapeutic response. However, results must always be interpreted alongside dermatological examination, nerve function assessment, and the patient’s full medication history to safely adjust multi-drug therapy and prevent immune-mediated complications.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Patient Advisory & Medication Safety

Medication Advisory

Do not discontinue or adjust any prescribed leprosy medication (dapsone, rifampicin, clofazimine) without consulting your treating physician. Sudden changes can trigger severe reactions including erythema nodosum leprosum (ENL) or reversal reactions requiring urgent specialist care.

Exclusion Criteria & Emergency Red Flags

Sample Collection Safety: Do not proceed with biopsy collection if the lesion site shows active bleeding, purulent discharge, or spreading cellulitis. Seek immediate medical attention instead.
Patient Conditions: Patients with severe neutropenia (ANC <500/µL) or uncontrolled coagulopathy should only undergo specimen collection in a hospital environment with haematology support.
Emergency Symptoms (go to ER): Rapidly worsening skin lesions with high fever, severe neuritic pain, vision loss, or respiratory distress.
Minors: A legal guardian must be present and provide written informed consent for specimen collection from individuals under 18 years of age, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.

Patient FAQ & Clinical Guidance

1. How does the M. leprae bacterial load test guide my treatment?

The test quantifies the exact number of leprosy bacilli before, during, and after multi-drug therapy, enabling your doctor to confirm bacterial clearance and adjust medications to prevent relapse or drug resistance.

2. Is home sample collection available for this test?

No. Sample collection for this test requires a punch biopsy or lesion curt from an anaesthetised site, which is classified as an invasive clinical procedure. All collections are performed strictly within accredited hospital facilities to ensure sterile technique and patient safety. Mobile home phlebotomy is not available.

3. What sample types are accepted for analysis?

We accept punch biopsies of skin lesions, ear lobe smears, nasal mucosal scrapings, and lesion curatings. All specimens must be collected inside a hospital setting by a qualified clinician using sterile, cold-chain protocols to preserve nucleic acid integrity for precise PCR quantification and sequencing.

4. How quickly will I receive my results?

Your report will be emailed within 36 hours of sample receipt. Critical notifications are provided via phone within 24 hours when clinically indicated.

5. Does this test detect drug resistance?

Yes. Whole Genome Sequencing simultaneously profiles mutations in genes associated with resistance to dapsone (folP1), rifampicin (rpoB), and ofloxacin (gyrA), providing actionable data for selecting effective therapy.

UAE Regulatory & Data Privacy Adherence

Data Privacy & Security: All patient data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and informed consent procedures adhere strictly to Federal Decree-Law No. 4 of 2016 on Medical Liability.

ISO Accreditation: ISO 9001:2015 Quality Management System — Certificate No. INT/EGQ/2509DA/3139.

Clinical & Logistical Metadata

Test Name	Mycobacterium leprae Bacterial Load Test (qPCR + WGS)
Price (AED)	800 AED
Turnaround Time	24–36 Hours from Sample Receipt
Sample Type / Matrix	Punch Biopsy, Ear Lobe Smear, Nasal Mucosal Scraping, Lesion Curating – Hospital Extraction Only
Methodology Used	Quantitative Real-Time PCR (qPCR) + Whole Genome Sequencing (WGS)
ICD-10-CM Code	A30.9 (Leprosy, unspecified), A30.5 (Lepromatous leprosy)
LOINC Code	98515-7 (Mycobacterium leprae DNA [Log #/volume] in Specimen by NAA with probe detection)
DHA Facility License & Address	DHA Facility License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE